The pharmaceutical world is seeing a remarkable shift in blood sugar therapy with the arrival of GLP-1 transdermal devices. These patches offer a possibly more convenient alternative to subcutaneous administrations of GLP-1 drugs, minimizing the requirement of daily needle pricks. The technology